Sheri Holmen, PhD, was the first to show that IDH mutations, on the appropriate genetic background, resulted in glioma initiation and growth. This discovery provided the basis of a pre-clinical model for testing the contribution of other molecular alterations to the pathogenesis of, and the effects of various treatments on, these tumors. Howard Colman, MD, PhD, and colleagues subsequently demonstrated that increased DNA alterations were associated with higher-grade gliomas and worse prognoses. Continue reading → The Role of IDH Mutation in Human Brain Tumors
Adam Cohen, MD, MS is a researcher and physician at Huntsman Cancer Institute, specializing in brain cancer and breast cancer. He is also an assistant professor in the departments of Internal Medicine (Division of Oncology) and Neurosurgery at the University of Utah. Cohen came to HCI in 2009 to study brain and women’s cancers. Cohen’s research focuses on clinical trials that provide his patients personalized treatments.
Huntsman Translational Scholars: Adam Cohen, MD, MS